TrialPath

Find a study

Match me to a study

129 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

120 studies on the map

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamComparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study — Northern Arizona Healthcare, FlagstaffA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine — Rehabilitation & Neurological Services /ID# 248517, HuntsvilleEfficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects — The Belinga Clinic, Fort SmithStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine — Mayo Clinic Hospital, PhoenixA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine — TrialSphere Corp, Merz Investigational Site #0010513, ChandlerA Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years — Rehabilitation and Neurological Services /ID# 270782, HuntsvilleCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine — Yale-New Haven Children's Hospital - PIN, New HavenA Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine — Xenoscience Inc, PhoenixA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Research Site, FoleyEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Chandler Clinical Research Trials- Site Number : 8400025, ChandlerA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Research Site, CullmanA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — UAB Lung Health Center, BirminghamEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine — Central Research Associates /ID# 260161, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — GSK Investigational Site, SheffieldClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, BirminghamA Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine — Yale University School of Medicine, New HavenA Study of Eptinezumab in Pediatric Participants With Episodic Migraine — Ki Health Partners LLC DBA New England Institute for Clinical Research, StamfordA Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamQudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old — Upsher-Smith Clinical Trial Site #5, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, BirminghamA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine — Central Research Associates, LLC (CRA) dba Flourish Research, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenA Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults — Central Research Associates, BirminghamA Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine — Flourish - Birmingham, BirminghamSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandStudy of EVO756 in Adults With Migraine — CA Medical Clinic for Headache, Los AngelesA Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine — Arkansas Children's Hospital, Little RockTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, BirminghamLong-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Perseverance Research Center, LLC, ScottsdaleMulti-Center Clean Air Randomized Controlled Trial in COPD — University of Alabama, Lung Health Center, BirminghamStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) — Rehabilitation & Neurological Services /ID# 229969, HuntsvilleRandomized Study in Children and Adolescents With Migraine: Acute Treatment — Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, BirminghamRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine — Hope Clinical Research, Canoga ParkZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Research Site, AthensDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) — GSK Investigational Site, Loxahatchee GrovesEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkEffect of Ensifentrine on Sputum Markers of Inflammation in COPD — University of Alabama at Birmingham, BirminghamSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamStudy Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients — Sunwise Clinical Research, Llc, Walnut CreekA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — GSK Investigational Site, DoralEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaTrial to Determine Effective Aspirin Dose in COPD — Johns Hopkins Bayview Medical Center, BaltimoreLung and Bone Marrow Transplantation for Lung and Bone Marrow Failure — UPMC Presbyterian, PittsburghArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency — University of Alabama at Birmingham, BirminghamFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD — University of Tennessee Medical Center, Knoxville: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators — The University of Tennessee Graduate School of Medicine, KnoxvilleThe Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) — UCSF Airway Clinical Research Center, San FranciscoHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityInhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Duke Asthma Allergy and Airway Center, DurhamHyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy — University of Virginia Health System, CharlottesvillePulmonary Hypertension SOLAR — Duke University Medical Center, DurhamThe Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) — UCSD Sleep Research, La JollaPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.Cognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamStudy of Panobinostat (LBH589) in Patients With Sickle Cell Disease — Augusta University, AugustaAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, ValhallaMethylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoPartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaHematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies — Boston Children's Hospital, BostonHaploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease — City of Hope Medical Center, DuarteStudy to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisT-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) — Cincinnati Children's Hospital Medical Center, CincinnatiRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.Gene Editing For Sickle Cell Disease — St. Jude Children's Research Hospital, MemphisBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonEfficacy of Nerve Blocks for Episodic Migraine — Mayo Clinic in Rochester, RochesterRimegepant as Preemptive Treatment for Predictable Trigger-Induced Migraine in Adult Patients in the US — MedStar Health: Neurology at McLean, McLeanEffectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines — Advocate Christ Medical Center Emergency Department, Oak LawnBilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines — Neuroscience Institute at Great Neck, Great NeckBOTOX® vs. XEOMIN® for Chronic Migraine — Naval Medical Center Camp Lejeune, JacksonvilleEffectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications — Mayo Clinic in Arizona, PhoenixA Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache — Maimonides Medical Center, BrooklynClinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain — Peter H Hwang, Stanford